Clinical Trial Update: Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany

View source ↗

Summary

A completed prospective trial assessing palivizumab (Synagis) in high-risk children in Germany with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Synagis (palivizumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Respiratory Syncytial Virus Infections | Status: COMPLETED | Results posted: 2018-10-29